For too long, sepsis care has operated by a playbook that manages but doesn't conquer. 

At Eliaz Therapeutics, we believe it's time to rewrite those rules. 

When facing a crisis like sepsis, standardized protocols known as "care bundles" are essential for rapid response. 

​They ensure timely supportive actions. However, these important checklists don't—and can't—address the fundamental biological storm raging within the patient: the dysregulated immune response.

This is where Eliaz Therapeutics offers a transformative difference.

❌ THE CRITICAL GAP

Protocols manage symptoms; they don't neutralize the core drivers of sepsis.

✅ OUR SOLUTION

XGal-3® is engineered to directly target and remove Galectin-3—a key protein scientifically recognized for fueling that destructive internal cascade. Our technology aims to go beyond supportive measures to actively resolve the underlying pathology.

💡 YOUR INVESTMENT OPPORTUNITY

Your investment directly supports the next crucial steps for XGal-3®: completing safety studies, preparing for human trials slated for late 2025, and scaling our FDA-designated Breakthrough Device. 

As an Eliaz Therapeutics investor, you’re helping build the solution to a $62B market desperate for solutions—and part of a mission to save millions of lives. 

Join the fight against sepsis!

With gratitude, 

The Eliaz Therapeutics Team